Wellington Management Group’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$480M Buy
6,391,816
+131,491
+2% +$10.4M 0.09% 210
2025
Q4
$495M Sell
6,260,325
-328,486
-5% -$24.7M 0.09% 207
2025
Q3
$431M Buy
6,588,811
+243,035
+4% +$11.9M 0.08% 229
2025
Q2
$251M Sell
6,345,776
-2,070,645
-25% -$67.8M 0.05% 313
2025
Q1
$254M Sell
8,416,421
-255,727
-3% -$8.37M 0.05% 291
2024
Q4
$303M Sell
8,672,148
-63,639
-0.7% -$2.38M 0.06% 276
2024
Q3
$350M Buy
8,735,787
+2,166,979
+33% +$101M 0.06% 268
2024
Q2
$313M Buy
6,568,808
+873,109
+15% +$35.8M 0.06% 290
2024
Q1
$247M Buy
5,695,699
+1,078,721
+23% +$51.4M 0.04% 351
2023
Q4
$234M Buy
4,616,978
+2,856,353
+162% +$137M 0.04% 362
2023
Q3
$79.9M Buy
1,760,625
+845,902
+92% +$34.9M 0.02% 587
2023
Q2
$37.5M Buy
+914,723
New +$35.2M 0.01% 781
2022
Q1
Sell
-13,134
Closed -$399K 2159
2021
Q4
$399K Buy
+13,134
New +$413K ﹤0.01% 2024
2021
Q3
Sell
-5,911
Closed -$236K 2203
2021
Q2
$236K Buy
+5,911
New +$232K ﹤0.01% 2069
2020
Q4
Sell
-868,993
Closed -$41.2M 1962
2020
Q3
$41.2M Sell
868,993
-863,371
-50% -$48M 0.01% 743
2020
Q2
$102M Sell
1,732,364
-2,252,853
-57% -$125M 0.02% 515
2020
Q1
$188M Sell
3,985,217
-2,752,639
-41% -$153M 0.05% 312
2019
Q4
$407M Sell
6,737,856
-1,007,483
-13% -$60M 0.09% 226
2019
Q3
$464M Buy
7,745,339
+87,140
+1% +$5.68M 0.1% 203
2019
Q2
$492M Buy
7,658,199
+119,123
+2% +$8.42M 0.11% 209
2019
Q1
$612M Sell
7,539,076
-87,929
-1% -$5.67M 0.14% 167
2018
Q4
$412M Sell
7,627,005
-1,668,160
-18% -$85.1M 0.1% 204
2018
Q3
$479M Buy
9,295,165
+46,804
+0.5% +$2.2M 0.1% 216
2018
Q2
$385M Sell
9,248,361
-705,581
-7% -$31.3M 0.09% 243
2018
Q1
$439M Sell
9,953,942
-943,091
-9% -$47.9M 0.1% 221
2017
Q4
$548M Sell
10,897,033
-519,326
-5% -$28.5M 0.12% 190
2017
Q3
$579M Buy
11,416,359
+914,349
+9% +$47.9M 0.13% 177
2017
Q2
$534M Buy
10,502,010
+1,141,457
+12% +$53.2M 0.13% 180
2017
Q1
$376M Buy
9,360,553
+3,364,621
+56% +$151M 0.09% 219
2016
Q4
$287M Buy
5,995,932
+2,903,235
+94% +$115M 0.07% 250
2016
Q3
$113M Buy
3,092,697
+2,676,228
+643% +$83.7M 0.03% 452
2016
Q2
$9.7M Sell
416,469
-10,640
-2% -$343K ﹤0.01% 1151
2016
Q1
$17.3M Buy
427,109
+1,407
+0.3% +$57.1K ﹤0.01% 967
2015
Q4
$26.4M Buy
425,702
+1,684
+0.4% +$90.9K 0.01% 877
2015
Q3
$17.1M Sell
424,018
-89,657
-17% -$4.64M ﹤0.01% 1022
2015
Q2
$29.6M Sell
513,675
-662,408
-56% -$42.1M 0.01% 882
2015
Q1
$74.9M Buy
1,176,083
+827,582
+237% +$56.1M 0.02% 606
2014
Q4
$21.5M Buy
348,501
+295,252
+554% +$14.6M 0.01% 1028
2014
Q3
$2.07M Sell
53,249
-385,630
-88% -$13.7M ﹤0.01% 1675
2014
Q2
$15.1M Sell
438,879
-117,555
-21% -$3.7M ﹤0.01% 1132
2014
Q1
$24M Sell
556,434
-98,325
-15% -$4.77M 0.01% 968
2013
Q4
$26.1M Buy
654,759
+487,959
+293% +$17.4M 0.01% 919
2013
Q3
$6.26M Buy
166,800
+108,400
+186% +$3.24M ﹤0.01% 1375
2013
Q2
$1.57M Buy
+58,400
New +$1.24M ﹤0.01% 1679

Other funds holding IONS

Wellington Management Group's IONS Position: Q1 2026 in Review

Wellington Management Group increased its Ionis Pharmaceuticals (IONS) stake by 2.1% in Q1 2026, buying an estimated $10.4M and bringing the position to 6,391,816 shares worth $480M. The position accounts for 0.09% of the portfolio, ranked #210.

Wellington Management Group first reported a position in IONS in Q2 2013 and has held it in 44 quarters since. The position peaked at $612M in Q1 2019. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Wellington Management Group held 6,391,816 shares of Ionis Pharmaceuticals worth $480M as of Q1 2026.
  • Wellington Management Group bought 131,491 Ionis Pharmaceuticals shares in Q1 2026, an estimated $10.4M.
  • Ionis Pharmaceuticals made up 0.09% of Wellington Management Group's portfolio in Q1 2026, its #210 holding.
  • Wellington Management Group first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • Wellington Management Group's Ionis Pharmaceuticals position peaked at $612M in Q1 2019.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.